rexahn PHARMACEUTICALS

NYSE MKT:	'RNN'	Market Capitalization:	$102 million
Recent Price (6/1/17):	$4.00	Shares Outstanding (5/5/17):	25.4 million
52-week Price Range:	$1.30 – $7.10	Burn Rate (per quarter):	$4 million
Avg Daily Volume (3m):	700K	Cash (3/31/17):	$21.5 million*

Analyst Coverage: ***FBR & Co.,*** Vernon Bernardino; ***H. C. Wainwright & Co.,*** Joe Pantginis; ***Laidlaw & Company Ltd,*** Yale Jen, Ph.D.; ***IFS Securities***, David Bouchey, Ph.D.

HEADQUARTERS

15245 Shady Grove Rd, #455
Rockville, MD 20850
www.rexahn.com

MANAGEMENT TEAM

Peter D. Suzdak, Ph.D., Chief Executive Officer, suzdakp@rexahn.com
Ely Benaim, MD, Chief Medical Officer, benaime@rexahn.com
Ted Jeong, D. Mgt., Chief Financial Officer, ted@rexahn.com
Lisa Nolan, Ph.D., Chief Business Officer, nolanl@rexahn.com

Business:

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class **targeted therapeutics** for the treatment of cancer. The Company's mission is to improve the lives of cancer patients by developing next generation cancer therapies that specifically **target cancer cells** leading to **increased efficacy** while **minimizing side effects** traditionally associated with cancer treatment.

Investment Highlights:

- **Deep Oncology Pipeline with 3 Novel Programs Advancing in Clinical Development**

Rexahn has a diversified oncology pipeline that includes 3 novel potentially best-in-class, or first-in-class, anti-cancer agents advancing in clinical development with **Phase IIa** clinical data available from all three programs during 2017.



* Company estimates for 2025 based on forecasted patient numbers and pricing for new medications from DataMonitor and GlobalData (June 2016)

- **RX-3117 Showed Efficacy in Hardest to Treat Patients in a Phase IIa Clinical Trial in Pancreatic Cancer and Bladder Cancer Patients**

In a **Phase IIa** clinical trial, in pancreatic cancer patients that have failed 3 or more prior cancer therapies, 20% of patients treated with RX-3117 exhibited progression free survival (PFS) of greater than 5.6 months. There are no approved treatments for pancreatic cancer patients who have failed two or more prior therapies. Also in a separate **Phase IIa** clinical trial in metastatic bladder cancer who had failed 3 or more prior therapies, RX-3117 increased PFS to 6 months in 20% of the patients.

- **Phase IIa Clinical Trial in Triple Negative Breast Cancer Initiated for Supinoxin™ Based on Preliminary Evidence of Single Agent Activity**

Rexahn recently presented **Phase I** clinical trial data demonstrating single agent activity of Supinoxin with evidence of stable disease in patients with breast, neuroendocrine and colorectal cancers. A **Phase IIa** clinical trial in patients with triple negative breast cancer was initiated in 1Q 2017 with an initial data readout in 3Q 2017.

- **Archexin® Shows Preliminary Evidence of Tumor Reduction in Metastatic Renal Cell Carcinoma Patients**

Initial data from a **Phase IIa** clinical trial of Archexin in metastatic renal cell carcinoma (mRCC) patients showed promising signals of clinical activity with dose- and time-dependent evidence of tumor reduction and stable disease. Data from the completed study will be available mid-2017.

- **Pursuing Corporate Partnership Opportunities to Maximize Shareholder Value**

Rexahn is continuing discussions with multiple oncology-focused pharmaceutical companies and seeks to maximize the potential value of its drug development programs in any partnering transactions.

*** Does not include cash Inflow from $10M financing in June 2017; Includes $3M in warrant exercises that occurred after March 31, 2017**

RX-3117: 2 Phase IIa Clinical Trials

RX-3117 is an orally-administered next generation, cancer cell specific nucleoside agent that induces apoptotic cell death selectively in cancer cells. RX-3117 is currently in **Phase IIa** clinical trials in both metastatic pancreatic cancer and muscle invasive bladder cancer.

Phase IIa:

Metastatic pancreatic cancer: RX-3117 treatment produced progression free survival in 20% of the patients of greater than 5.6 months (with one patient having progression free survival of 7.2 months). These patients had already failed 3 or more prior cancer therapies. Current options for these patients are usually limited to palliative or best supportive care and these patients normally have an expected survival of less than 2 months. An additional 40 metastatic pancreatic cancer patients are now being enrolled into the study and this data will be available in 3Q 2017.

Metastatic bladder cancer: RX-3117 treatment produced progression free survival in 20% of the patients of greater than 6 months. These patients had already failed 3 or more prior cancer therapies and normally have a PFS of 2 months.

Development Strategy:

Pursue clinical development in pancreatic cancer patients who have failed two or more prior anti-cancer therapies - No drug is currently approved for this indication, thus RX-3117 may be a candidate for an accelerated approval. RX-3117 will also be developed as a first line treatment and in combination with Abraxane® for newly diagnosed patients who have had no prior chemotherapy.

Supinoxin™: Phase I Clinical Trial

Supinoxin™ is an orally-administered, highly-potent, first-in-class anti-cancer small molecule that blocks cancer cell growth through inhibition of phosphorylated p68 which is found predominantly in cancer cells.

Phase I:

Supinoxin is safe and well tolerated with early evidence of potential anti-tumor activity in cancer patients (data presented at ASCO 2016). In the study, 5 patients with neuroendocrine, breast or colorectal cancers exhibited stable disease for up to 746 days, despite having failed multiple prior anti-cancer treatments.

Phase IIa:

A Phase IIa clinical study in triple negative breast cancer patients was initiated in 1Q 2017 with an interim data readout in 3Q 2017.

Archexin®: Phase IIa Clinical Trial

Archexin® is a unique anti-cancer drug candidate which inhibits the activated form of the cancer cell signaling protein phosphorylated-Akt1 which is only found in cancer cells and is involved in cancer cell growth and drug resistance.

Phase IIa:

Archexin® is in the middle of a Phase IIa clinical trial in patients with metastatic renal cell (kidney) cancer.



Clinical data from initial part of the trial showed early evidence of potential dose- and time-dependent tumor reduction. Patients experienced reductions in their tumors ranging up to 36%, and exhibited stable disease (data presented at ASCO 2016). The randomized efficacy portion of the clinical trial is ongoing and data should be available mid-2017.

Upcoming 2017 Clinical Milestones		Timing
RX-3117	Clinical data from stage 2 of a **Phase IIa** clinical Proof-of-Concept trial in metastatic pancreatic cancer patients	3Q
	Clinical data from stage 1 of a **Phase IIa** clinical Proof-of-Concept trial in metastatic bladder cancer	✓
Supinoxin™	Complete ongoing **Phase I** dose escalation trial, determine recommended Phase IIa dose and initiate a **Phase IIa** proof-of concept trial in triple negative breast cancer	✓
	Report interim data from stage 1 of a **Phase IIa** proof-of-concept clinical trial in triple negative breast cancer	3Q
Archexin®	Initial data readout from Archexin® **Phase IIa** clinical proof-of-concept trial in metastatic renal cell carcinoma	Mid 2017